
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is benefiting from unusually strong execution, with Q3'26 revenue of $139M (+39% Y/Y), Adj. EBITDA of $30M, 74% gross margins, and $250M of cash with no debt, while its core transplant volumes rose 21% Y/Y to nearly 61k. The bullish case is reinforced by the favorable CMS transplant LCD, which removed a major reimbursement overhang and preserved the HeartCare bundle, giving the company a clearer runway for higher volumes and ASPs across kidney, heart, and lung testing. Management also has credible growth vectors beyond transplant, including Naveris in oncology MRD, the planned AlloHeme launch in 2027, and expanded Epic integration, all supported by a strong competitive position and improving revenue cycle management.
Bears say
CareDx is exposed to a narrow revenue base, with financial results heavily reliant on AlloSure Kidney and AlloMap Heart, making the company vulnerable if reimbursement or utilization fails to scale as expected. Its growth strategy also depends on commercializing new transplant diagnostics, but those programs require substantial R&D, clinical validation, approvals, and years of development, while the underlying transplant testing market is evolving rapidly. Adoption risk remains high because clinicians and healthcare administrators may be slow to change historical practices due to liability and reimbursement concerns, limiting uptake of AlloSure Kidney, AlloMap Heart, and other solutions.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About CareDx (CDNA) Forecast
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares